List of Excipients in Branded Drug NESACAINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein Inc	NESACAINE	chloroprocaine hydrochloride	0404-9927	EDETATE DISODIUM
Henry Schein Inc	NESACAINE	chloroprocaine hydrochloride	0404-9927	HYDROCHLORIC ACID
Henry Schein Inc	NESACAINE	chloroprocaine hydrochloride	0404-9927	METHYLPARABEN

NESACAINE Excipient Strategy and Commercial Opportunities for Chloroprocaine Injection

Last updated: September 9, 2026

Nesacaine is a chloroprocaine hydrochloride injectable local anesthetic used for infiltration, peripheral nerve block, caudal and epidural anesthesia. Its active ingredient is generic and long established. Commercial differentiation therefore depends primarily on preservative status, concentration, container closure, ready-to-use presentation, stability, administration compatibility, and hospital purchasing economics rather than new-molecule patent protection.

What is Nesacaine and which formulations are commercially relevant?

Nesacaine contains chloroprocaine hydrochloride, an ester-type local anesthetic. U.S. labeling identifies injectable concentrations including 1%, 2%, and 3%, with preservative-free Nesacaine-MPF presentations intended for clinical use where antimicrobial preservatives are undesirable.[1]

Product attribute	Commercial relevance
Active ingredient	Chloroprocaine hydrochloride
Dosage form	Sterile injectable solution
Common concentrations	1%, 2%, and 3%
Administration routes	Local infiltration, peripheral nerve block, caudal and epidural use
Preservative-free option	Nesacaine-MPF
Primary customers	Hospitals, ambulatory surgery centers, anesthesia departments, obstetric units
Key formulation risks	Sterility, pH, particulate matter, container compatibility, local tolerability
Main differentiation path	Presentation, workflow, preservative status, supply reliability, and price

Chloroprocaine is hydrolyzed rapidly by plasma esterases. The formulation strategy must preserve chemical stability in the container while supporting predictable local anesthetic performance after administration.[1]

What excipients are used in Nesacaine formulations?

The core excipient system is comparatively simple. Public product information identifies sodium chloride as a tonicity-adjusting agent in relevant injectable presentations, with hydrochloric acid and sodium hydroxide used as pH adjusters where applicable.[1,2]

Preservative-containing and preservative-free strategies

The central excipient decision is whether the product is supplied as a multidose formulation containing an antimicrobial preservative or as a preservative-free, single-dose product.

Preservative-free formulation is commercially important for neuraxial and epidural applications. Methylparaben and related antimicrobial preservatives can create clinical restrictions in products intended for administration into sensitive anatomical spaces. A preservative-free product also reduces concerns about preservative exposure in neonates, obstetric patients, and patients receiving repeated procedures.

A practical formulation architecture is:

Formulation component	Function	Strategic consideration
Chloroprocaine hydrochloride	Active ingredient	Controls concentration and dose volume
Sodium chloride	Isotonicity adjustment	Must be balanced against final osmolality and injection tolerability
Hydrochloric acid or sodium hydroxide	pH adjustment	Affects stability, solubility, and local tolerability
Water for injection	Vehicle	Must meet compendial quality requirements
Antimicrobial preservative, where used	Multidose microbial control	Limits suitability for some neuraxial applications
Nitrogen overlay, where justified	Oxygen reduction	May support stability but adds packaging and process complexity

The simplest preservative-free formulation is generally the strongest platform for hospital anesthesia use. It minimizes excipient-related clinical objections and allows the product to target both routine local anesthesia and higher-value neuraxial procedures.

Which excipient attributes create commercial differentiation?

Preservative-free presentation

Preservative-free status is the most commercially important excipient-related attribute. It supports use in epidural and other neuraxial procedures and can reduce pharmacy segregation between general-use and neuraxial-use products.

The commercial value is greater when the product is supplied in a clearly labeled single-dose container. Label design, tamper evidence, barcode quality, and visibility of "preservative-free" status can affect operating-room adoption.

Low-excipient composition

A short excipient list simplifies hospital formulary review and reduces the number of compatibility questions raised by anesthesia departments. A low-excipient formulation also limits the number of extractables, leachables, and degradation pathways requiring long-term evaluation.

Osmolality and pH control

Local anesthetic injections can cause pain or tissue irritation when pH or osmolality deviates materially from physiological conditions. A formulation program should control:

• pH across the labeled shelf life;
• osmolality and tonicity;
• visible and subvisible particles;
• degradation products;
• container interaction;
• precipitation after admixture or dilution.

Excipient selection should be supported by stability-indicating analytical methods rather than by composition alone.

What formulations are protected by patents?

Nesacaine is based on an old small-molecule active ingredient. Composition-of-matter patent protection for chloroprocaine is not a meaningful commercial barrier. The relevant intellectual-property opportunities are more likely to involve:

1. Specific concentration and dose presentations.
2. Ready-to-use prefilled syringes.
3. Container-closure systems.
4. Extended shelf-life formulations.
5. Low-particulate or low-degradation formulations.
6. Manufacturing processes that improve sterility assurance or reduce impurity formation.
7. Combination products with standardized procedural kits.
8. Formulations optimized for epidural or obstetric administration.

A formulation patent would need a defensible technical distinction, such as an unexpected stability profile, improved impurity control, reduced administration pain, or a clinically meaningful compatibility advantage. A claim limited to routine use of sodium chloride and pH adjustment would face substantial obviousness risk.

The FDA Orange Book should be checked for current listed patents associated with the specific Nesacaine reference product and dosage form. The label itself does not establish a meaningful active patent estate.[1,3]

When does Nesacaine lose exclusivity?

Nesacaine is an established generic injectable product, so commercial exclusivity is principally determined by generic approval status, manufacturing economics, supply reliability, and any surviving formulation or process rights. New-drug exclusivity and composition-of-matter exclusivity are not the primary barriers for chloroprocaine injection.

Exclusivity category	Relevance to Nesacaine
Composition-of-matter patent	Not commercially material for this established active ingredient
New chemical entity exclusivity	Not applicable to the legacy active ingredient
Pediatric exclusivity	No central role in the current product opportunity
Formulation patent	Possible, but must provide a real technical advantage
Method-of-use patent	Narrow potential; depends on a specific approved use and claim scope
Generic approval barrier	Abbreviated New Drug Application requirements, including CMC and bioequivalence considerations where applicable
Manufacturing barrier	Sterile injectable capability, validation, and supply continuity

Because the product is an injectable, the practical entry barrier can exceed the apparent patent barrier. Sterile manufacturing capacity, container qualification, process validation, inspection history, and hospital supply contracts can determine market access.

What FDA regulatory status applies to Nesacaine?

Nesacaine is regulated as a prescription sterile injectable drug. A generic developer would generally pursue an ANDA if the proposed product can meet the applicable requirements for sameness, pharmaceutical equivalence, bioequivalence where required, and quality.[4]

The regulatory program must address:

• Active ingredient identity and strength;
• Sterility and bacterial endotoxin control;
• Particulate matter;
• Container-closure integrity;
• Extractables and leachables;
• Stability through the proposed shelf life;
• In-process controls;
• aseptic processing or terminal sterilization, if technically feasible;
• labeling for preservative status and route of administration.

For a preservative-free single-dose product, the manufacturer must demonstrate that the packaging configuration maintains sterility through the labeled shelf life. For a multidose product, antimicrobial effectiveness and repeated-entry use become additional development burdens.

What commercial opportunities exist for Nesacaine excipients?

Ready-to-use prefilled syringes

A prefilled syringe can reduce pharmacy compounding, preparation time, and medication-selection errors. The opportunity is strongest for anesthesia departments and ambulatory surgery centers where standardized procedural trays are valued.

The device must be evaluated for:

• Chloroprocaine adsorption or interaction with syringe materials;
• Silicone oil and subvisible particle generation;
• Plunger and stopper compatibility;
• Extractables and leachables;
• Dose accuracy;
• Needle or luer configuration;
• Human factors and labeling.

Unit-dose ampoules and low-volume vials

Unit-dose packaging can improve inventory control and reduce wastage. Low-volume presentations may be attractive where the clinical dose is predictable, especially in obstetric anesthesia and short procedures.

The commercial tradeoff is that smaller containers increase packaging cost per milliliter. The product must generate enough workflow or waste-reduction value to justify the premium.

Extended shelf-life products

A formulation and packaging program that achieves a longer shelf life can reduce hospital stockouts and improve wholesaler inventory efficiency. The strongest technical opportunity is not necessarily a new excipient. It may be a better combination of pH control, oxygen management, container selection, and sterilization conditions.

Standardized anesthesia kits

Chloroprocaine can be incorporated into procedure-specific kits containing syringes, labels, filters, and administration accessories. Kit-based commercialization can create switching costs and simplify operating-room procurement, although it raises combination-product and supply-chain complexity.

Supply-constrained generic positioning

Sterile injectable shortages can create commercial openings for manufacturers with reliable capacity. A preservative-free chloroprocaine product with multiple concentrations and dependable distribution may compete effectively even without a novel formulation patent.

How strong is the patent estate for Nesacaine?

The patent estate is likely weak at the active-ingredient level and potentially moderate only for differentiated delivery or packaging technology.

IP category	Relative strength	Commercial assessment
Chloroprocaine composition	Low	Legacy molecule
Basic aqueous injection	Low	Conventional formulation technology
Preservative-free formulation	Low to moderate	Patentability depends on unexpected technical results
Prefilled syringe	Moderate	Device and compatibility claims may be available
Stability-enhanced formulation	Moderate	Requires robust comparative data
Procedure-specific kit	Moderate	Combination and device claims may provide limited protection
Manufacturing process	Moderate	May protect know-how more effectively than broad patents
Method of use	Low to moderate	Depends on narrow clinical claims and regulatory support

Trade secrets covering sterilization cycles, impurity control, filling parameters, and container selection may have greater practical value than broad excipient patents.

Which companies are challenging or competing with Nesacaine?

Competition is expected from manufacturers of generic chloroprocaine hydrochloride injection and from alternative local anesthetics, including lidocaine, mepivacaine, bupivacaine, ropivacaine, and tetracaine.

The competitive comparison is driven by onset, duration, toxicity profile, route-specific familiarity, cost, availability, and packaging.

Product class	Typical commercial advantage	Limitation versus chloroprocaine
Chloroprocaine	Rapid hydrolysis and short duration	Smaller market and lower manufacturing scale
Lidocaine	Broad availability and low cost	Different duration and toxicity considerations
Bupivacaine	Longer duration	Greater cardiotoxicity concern and slower offset
Ropivacaine	Long duration with established regional anesthesia use	Higher acquisition cost
Tetracaine	Potent local anesthetic activity	Different duration and safety profile

Generic competition may appear through ANDA approvals rather than Paragraph IV litigation. A Paragraph IV challenge would be relevant only if the reference product had an unexpired listed patent. Given the age of chloroprocaine injection, the principal risk is likely commercial price competition rather than patent litigation.

What litigation and settlement risks affect Nesacaine?

No major litigation or settlement position should be assumed without a current review of PACER, FDA Orange Book listings, and approved-product databases. The likely legal exposure for a new entrant is conventional:

• Patent claims directed to a specific container or delivery device;
• Trade-secret disputes involving sterile manufacturing;
• Contract disputes with hospital or distributor customers;
• Product-liability claims involving dosing, labeling, sterility, or administration;
• Regulatory enforcement related to sterile manufacturing deficiencies.

Settlement agreements are generally less likely to shape the market than manufacturing capacity and procurement contracts unless a later entrant owns a live formulation or device patent.

What generic launch scenarios exist?

Scenario 1: Low-cost vial launch

A manufacturer launches a conventional preservative-free vial in one or more concentrations. The strategy competes on price, supply continuity, and wholesaler access. Patent risk is low, but margin pressure is high.

Scenario 2: Premium ready-to-use launch

A supplier introduces prefilled syringes or procedure-specific packaging. The product seeks premium pricing through labor savings, error reduction, and operating-room convenience.

Scenario 3: Portfolio launch

The supplier offers 1%, 2%, and 3% strengths with consistent packaging and a single hospital contract. This can improve formulary adoption and reduce competitor substitution.

Scenario 4: Supply-resilience launch

The manufacturer targets hospitals affected by injectable shortages. The value proposition is redundant manufacturing, predictable allocation, and transparent inventory commitments.

Key Takeaways

• Nesacaine contains chloroprocaine hydrochloride and is commercially differentiated through formulation, packaging, and supply performance.
• Preservative-free presentation is the strongest excipient-related opportunity, particularly for epidural and neuraxial use.
• Sodium chloride, water for injection, and pH adjusters support a simple formulation architecture.
• Broad patents covering routine chloroprocaine injection excipients are unlikely to provide durable protection.
• Prefilled syringes, low-volume unit doses, stability improvements, and procedure kits offer more defensible commercial opportunities.
• Sterile manufacturing capability and hospital supply reliability are more important barriers than active-ingredient patent rights.
• Generic launch economics will depend on manufacturing scale, procurement contracts, shortage conditions, and the ability to reduce preparation and medication-use costs.

FAQs

Is Nesacaine preservative-free?

Nesacaine-MPF is identified as a preservative-free presentation. Product-specific labeling should be used to confirm the exact concentration, container, and excipient profile.[1]

Which excipient is most important for chloroprocaine injection?

The most important excipient-related decision is whether the product contains an antimicrobial preservative. Preservative-free status expands suitability for neuraxial and epidural applications.

Can a new chloroprocaine formulation receive patent protection?

Possibly, but a patent application would need a specific technical advantage, such as improved stability, reduced impurities, superior container compatibility, or a commercially meaningful delivery configuration.

Is chloroprocaine subject to biosimilar competition?

No. Chloroprocaine is a small-molecule drug, so competing products would generally be generics rather than biosimilars.

What is the strongest commercial format for Nesacaine?

A preservative-free, ready-to-use, unit-dose or prefilled presentation is the strongest differentiation format where it produces measurable workflow, waste, or medication-safety benefits.

References

1. Pfizer Inc. (2023). Nesacaine and Nesacaine-MPF: Chloroprocaine hydrochloride injection, USP prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Pharmacopeia. (2024). General chapter <1>: Injections and implanted drug products. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

6. International Council for Harmonisation. (2005). ICH Q9: Quality risk management.

7. U.S. Food and Drug Administration. (2004). Sterile drug products produced by aseptic processing: Current good manufacturing practice guidance for industry. FDA.